Plain-English translation of NCT07413042 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new combination treatment for people with advanced small cell lung cancer who have completed their initial chemotherapy. The study combines Injection, a radioactive treatment, with tislelizumab, a medication that helps your immune system fight cancer. Researchers want to see if this combination is safe and effective when given as maintenance treatment (ongoing care after initial chemotherapy).
Advanced small cell lung cancer is difficult to treat, and most patients eventually relapse after initial chemotherapy. This medication may offer a new approach by delivering radiation directly to cancer cells while boosting the body's natural immune defenses to keep the cancer from coming back.
You likely qualify if…
You likely don't qualify if…
You would receive the immune-boosting medication (tislelizumab) as an infusion every 3 weeks at a fixed dose of 200mg. You would also receive the radioactive injection () once every 6 weeks, with a maximum of 4 doses total. Your participation would involve regular clinic visits for infusions, blood tests to monitor your health and how well the treatment is working, and scans to assess your cancer over time. The study aims to enroll 24 patients and is currently recruiting.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China